High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma

Mutations in SETD2, a histone H3 lysine trimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is unclear if loss of SETD2 function alters the genomic distribution of histone 3 lysine 36 trimethylation (H3K36me3) in ccRCC. Furthermore, published epigenomic profiles are not specific to H3K36me3 or metastatic tumors. To determine if progressive SETD2 and H3K36me3 dysregulation occurs in metastatic tumors, H3K36me3, SETD2 copy number (CN) or SETD2 mRNA abundance was assessed in two independent cohorts: metastatic ccRCC (n=71) and the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma data set (n=413). Although SETD2 CN loss occurs with high frequency (>90%), H3K36me3 is not significantly impacted by monoallelic loss of SETD2. H3K36me3-positive nuclei were reduced an average of ~20% in primary ccRCC (90% positive nuclei in uninvolved vs 70% positive nuclei in ccRCC) and reduced by ~60% in metastases (90% positive in uninvolved kidney vs 30% positive in metastases) (P<0.001). To define a kidney-specific H3K36me3 profile, we generated genome-wide H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cell carcinoma (RCC) cell lines using chromatin immunoprecipitation coupled with high-throughput DNA sequencing and RNA sequencing. SETD2 loss of methyltransferase activity leads to regional alterations of H3K36me3 associated with aberrant RNA splicing in a SETD2 mutant RCC and SETD2 knockout cell line. These data suggest that during progression of ccRCC, a decline in H3K36me3 is observed in distant metastases, and regional H3K36me3 alterations influence alternative splicing in ccRCC.

[1]  Song Liu,et al.  Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma , 2014, Oncogene.

[2]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[3]  Eric Nestler,et al.  ngs.plot: Quick mining and visualization of next-generation sequencing data by integrating genomic databases , 2014, BMC Genomics.

[4]  J. Desterro,et al.  SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint , 2014, eLife.

[5]  A. Hyman,et al.  Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their Readers , 2010, Cell.

[6]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[7]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[8]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[9]  Joel S Parker,et al.  Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects , 2014, Genome research.

[10]  T. Cooper,et al.  Pre-mRNA splicing in disease and therapeutics. , 2012, Trends in molecular medicine.

[11]  J. Ahringer,et al.  Differential chromatin marking of introns and expressed exons by H3K36me3 , 2008, Nature Genetics.

[12]  S. Armstrong,et al.  Mutations in epigenetic regulators including SETD2 are gained during relapse in pediatric acute lymphoblastic leukemia , 2014, Nature Communications.

[13]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[14]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[15]  Leif E. Peterson,et al.  Reproducibility and Performance of Virtual Karyotyping With SNP Microarrays for the Detection of Chromosomal Imbalances in Formalin-fixed Paraffin-embedded Tissues , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  T. Cooper,et al.  Muscleblind proteins regulate alternative splicing , 2004, The EMBO journal.

[17]  E. Wagner,et al.  Understanding the language of Lys36 methylation at histone H3 , 2012, Nature Reviews Molecular Cell Biology.

[18]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[19]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[20]  A. Sood,et al.  Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer , 2011, Clinical Cancer Research.

[21]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[22]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[23]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[24]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[25]  Wei Yang,et al.  The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.

[26]  F. He,et al.  Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. , 2008, Cellular signalling.

[27]  B. Blencowe,et al.  Regulation of Alternative Splicing by Histone Modifications , 2010, Science.

[28]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[29]  Nhi N. Y. Vo,et al.  GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. , 2010, Cancer research.

[30]  R. Millikan,et al.  Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Zhiguo Zhang,et al.  Bioinformatics Strategies for Identifying Regions of Epigenetic Deregulation Associated with Aberrant Transcript Splicing and RNA-editing , 2015, BIOINFORMATICS.

[32]  Yuchen Jiao,et al.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas , 2014, Genes, chromosomes & cancer.

[33]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[34]  Stacey D. Finley,et al.  Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms , 2012, The AAPS Journal.

[35]  S. Sarkar,et al.  SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability , 2014, Cell reports.

[36]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[37]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[38]  L. Truong,et al.  Virtual-Karyotyping With SNP Microarrays in Morphologically Challenging Renal Cell Neoplasms: A Practical and Useful Diagnostic Modality , 2009, The American journal of surgical pathology.

[39]  Hong Li,et al.  Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling , 2010, Proceedings of the National Academy of Sciences.

[40]  A. Emili,et al.  Discovery of a chemical probe for the L3MBTL3 methyl-lysine reader domain , 2012, Nature chemical biology.

[41]  E. Jonasch,et al.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis , 2011, Modern Pathology.

[42]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[43]  L. Mahadevan,et al.  Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation , 2007, The EMBO journal.

[44]  P. Tamboli,et al.  Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma , 2009, Cancer.